INTERNATIONAL JOURNAL OF MICROBIAL SCIENCE

Publication Duration: Submission to first decision of acceptance – 16 days (two weeks), Acceptance to Publication: Maximum 8 Days (one week), Acceptance rate:10%, Article Processing Charges- Rs.3000/- (For Indian Authors), 38.70 Dollars (For others)

References

 

  1. Canouï, E., & Launay, O. (2019). Histoire et principes de la vaccination [History and principles of vaccination]. Revue des maladies respiratoires,  36(1), 74–81. https://doi.org/10.1016/j.rmr.2018.02.015
  2. Cunningham, A. L., Garçon, N., Leo, O., Friedland, L. R., Strugnell, R., Laupèze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing. Vaccine, 34(52),6655–6664. https://doi.org/10.1016/j.vaccine.2016.10.016
  3. Blattner, C., Lee, J. H., Sliepen, K., Derking, R., Falkowska, E., de la Peña, A. T., Cupo, A., Julien, J. P., van Gils, M., Lee, P. S., Peng, W., Paulson, J. C., Poignard, P., Burton, D. R., Moore, J. P., Sanders, R. W., Wilson, I. A., & Ward, A. B. (2014). Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity, 40(5),669–680. https://doi.org/10.1016/j.immuni.2014.04.008
  4. Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., Lui, S. F., Szeto, C. C., Chung, S., & Sung, J. J. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. The New England journal of medicine,  348 (20), 1986–1994. https://doi.org/10.1056/NEJMoa030685
  5. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K., Lau, E., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., … Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine,  382(13), 1199–1207. https://doi.org/10.1056/NEJMoa2001316
  6. World Health Organization (2020). https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
  7. Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: current knowledge. Virology journal, 16(1), 69. https://doi.org/10.1186/s12985-019-1182-0
  8. Malczyk, A. H., Kupke, A., Prüfer, S., Scheuplein, V. A., Hutzler, S., Kreuz, D., Beissert, T., Bauer, S., Hubich-Rau, S., Tondera, C., Eldin, H. S., Schmidt, J., Vergara-Alert, J., Süzer, Y., Seifried, J., Hanschmann, K. M., Kalinke, U., Herold, S., Sahin, U., Cichutek, K., … Mühlebach, M. D. (2015). A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. Journal of virology,  89(22), 11654–11667. https://doi.org/10.1128/JVI.01815-15
  9. Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., Li, J., … Qin, C. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science (New York, N.Y.), 369(6499), 77–81. https://doi.org/10.1126/science.abc1932
  10. Al-Kassmy, J., Pedersen, J., & Kobinger, G. (2020). Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses, 12(8), 861. https://doi.org/10.3390/v12080861
  11. Callaway E. (2020). Coronavirus vaccine trials have delivered their first results – but their promise is still unclear. Nature, 581(7809),363–364. https://doi.org/10.1038/d41586-020-01092-3
  12. Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) against Novel Coronavirus, Moderna, Inc. 2020. Available online: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine
  13. Amanat, F., & Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report.  Immunity, 52(4), 583–589. https://doi.org/10.1016/j.immuni.2020.03.007
  14. Noah C Peeri, Nistha Shrestha, Md Siddikur Rahman, Rafdzah Zaki, Zhengqi Tan, Saana Bibi, Mahdi Baghbanzadeh, Nasrin Aghamohammadi, Wenyi Zhang and Ubydul Haque. https://www.forbes.com/sites/moneyshow/2020/06/16/9-pharmaceutical-companies-racing-for-a-covid-19-vaccine/#7680f63476ad
  15. Yan-JunZhang, Gang Zeng, Hong-Xing Pan, Chang-Gui Li, Biao Kan, Ya-Ling Hu, Hai-Yan Mao, Qian Qian Xin, Kai Chu, Wei-Xiao Han, Zhen Chen, Rong Tang, Wei-Dong Yin, Xin Chen, Xue-Jie Gong, Chuan Qin, Yuan-Sheng Hu, Xiao-Yong Liu, Guo-Liang Cui, Cong-Bing Jiang, Heng-Ming Zhang, Jing-Xin Li, Min-Nan Yang, Xiao Juan Lian, Yan Song, Jin-Xing Lu, Xiang-Xi Wang, Miao Xu, Qiang Gao, Feng-Cai Zhu(2020). Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. MedRxiv. COVID-19 SARS-CoV2 preprints from medRxiv and bioRxiv. This article is a preprint and has not been peer-reviewed. doi: https://doi.org/10.1101/2020.07.31.20161216
  16. Osterhaus, A. D., & Rimmelzwaan, G. F. (1998). Induction of virus-specific immunity by iscoms. Developments in biological standardization, 92, 49–58.
  17. Magnusson, S. E., Reimer, J. M., Karlsson, K. H., Lilja, L., Bengtsson, K. L., & Stertman, L. (2013). Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine, 31(13), 1725–1733. https://doi.org/10.1016/j.vaccine.2013.01.039
  18. Reimer, J. M., Karlsson, K. H., Lövgren-Bengtsson, K., Magnusson, S. E., Fuentes, A., & Stertman, L. (2012). Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PloS one, 7(7),e41451. https://doi.org/10.1371/journal.pone.0041451
  19. Pedersen, G., Major, D., Roseby, S., Wood, J., Madhun, A. S., & Cox, R. J. (2011). Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza and other respiratory viruses, 5(6), 426–437. https://doi.org/10.1111/j.1750-2659.2011.00256.x
  20. Madhun, A. S., Haaheim, L. R., Nilsen, M. V., & Cox, R. J. (2009). Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine, 27(52), 7367–7376. https://doi.org/10.1016/j.vaccine.2009.09.044
  21. Radosević, K., Rodriguez, A., Mintardjo, R., Tax, D., Bengtsson, K. L., Thompson, C., Zambon, M., Weverling, G. J., Uytdehaag, F., & Goudsmit, J. (2008). Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine, 26(29-30),3640–3646. https://doi.org/10.1016/j.vaccine.2008.04.071
  22. Rajput, Z. I., Hu, S. H., Xiao, C. W., & Arijo, A. G. (2007). Adjuvant effects of saponins on animal immune responses. Journal of Zhejiang University. Science. B, 8(3), 153–161. https://doi.org/10.1631/jzus.2007.B0153
  23. Cox, R. J., Pedersen, G., Madhun, A. S., Svindland, S., Sævik, M., Breakwell, L., Hoschler, K., Willemsen, M., Campitelli, L., Nøstbakken, J. K., Weverling, G. J., Klap, J., McCullough, K. C., Zambon, M., Kompier, R., & Sjursen, H. (2011). Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine, 29(45),8049–8059. https://doi.org/10.1016/j.vaccine.2011.08.042
  24. Study of parenterally administrated adjuvanted seasonal influenza vaccine in healthy elderly volunteers. Identifier: NCT01444482.
  25. A (H7N9) VLP antigen dose-ranging study with Matrix-M1 adjuvant. Identifer: NCT02078674. [database on the Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02078674
  26. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L (2013). Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine, 31(13):1725–33. https://doi.org/ 10.1016/j.vaccine.2013.01.039
  27. Cox, F., Roos, A., Hafkemeijer, N., Baart, M., Tolboom, J., Dekking, L., Stittelaar, K., Goudsmit, J., Radošević, K., & Saeland, E. (2015). Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge. PloS one, 10(9), e0135723. https://doi.org/10.1371/journal.pone.0135723

Copyright © All rights reserved | Blogus by Themeansar.